Eingabe löschen




HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic

Auf einen Blick

  • Projektleiter/in : Prof. Dr. Rainer Riedl
  • Projektteam : Dr. Mark Sephton, Patrik Züger
  • Projektvolumen : CHF 1'382'297
  • Projektstatus : abgeschlossen
  • Drittmittelgeber : KTI (KTI-Projekt)
  • Projektpartner : BioVersys AG
  • Kontaktperson : Rainer Riedl


A new and highly innovative treatment will be realized by a novel and patentable orally available small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic bacterial strains.